Literature DB >> 274995

Prophylactic heparin therapy in acute promyelocytic leukemia.

R L Drapkin, T S Gee, M D Dowling, Z Arlin, S McKenzie, S Kempin, B Clarkson.   

Abstract

Twenty-four patients with acute promyelocytic leukemia were reviewed. Group I, treated between July 1970 and September 1973, received arabinosylcytosine and 6-thioguanine, and there was one complete remission, with 4/7 dying during induction with intracerebral hemorrhages, and 2/7 dying within one month. Group II, treated between May 1974 and March 1975, received daunomycin and arabinosylcytosine without heparin and 2/8 went into remission, with 6/8 dying during induction, 5 with intracerebral hemorrhages. Group III, treated between March 1975 and November 1976, received the identical chemotherapy as group II but with the addition of prophylactic heparin and there were 7/9 complete remissions, with 2/9 dying with intracerebral hemorrhages. In Group III there was an increased incidence of remission induction when compared to Group II (p less than .05) or when compared to Groups I and II combined (p less than .05). There was also a decreased incidence of fatal hemorrhage in Group III. This suggests that prophylactic heparin is useful during remission induction in acute promyelocytic leukemia.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 274995     DOI: 10.1002/1097-0142(197806)41:6<2484::aid-cncr2820410659>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

1.  Plasma levels of D-dimer: a crosslinked fibrin-degradation product in female breast cancer.

Authors:  C G Mitter; C C Zielinski
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 2.  Disseminated intravascular coagulation: diagnosis and management.

Authors:  K L Saving
Journal:  Indian J Pediatr       Date:  1987 May-Jun       Impact factor: 1.967

Review 3.  Advances in the management of adult acute myelogenous leukaemia.

Authors:  J A Whittaker
Journal:  Br Med J       Date:  1980-10-11

Review 4.  Acute promyelocytic leukaemia in the all trans retinoic acid era.

Authors:  T G DeLoughery; S H Goodnight
Journal:  Med Oncol       Date:  1996-12       Impact factor: 3.064

5.  Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group.

Authors:  T Haferlach; W Gassmann; H Löffler; C Jürgensen; J Noak; W D Ludwig; E Thiel; D Haase; C Fonatsch; R Becher
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

6.  Repeated complete remission in a patient with acute promyelocytic leukemia after treatment with 13-cis-retinoic acid first and with all-trans-retinoic acid in relapse.

Authors:  T Haferlach; H Löffler; B Glass; W Gassmann
Journal:  Clin Investig       Date:  1993-10

7.  Acute promyelocytic leukemia.

Authors:  E C Kingsley; B G Durie; H S Garewal
Journal:  West J Med       Date:  1987-03

8.  Disseminated intravascular coagulation in acute monoblastic leukemia: response to heparin therapy.

Authors:  A K Mangal; L Grossman; L Vickars
Journal:  Can Med Assoc J       Date:  1984-03-15       Impact factor: 8.262

9.  Treatment of promyelocytic leukemia during pregnancy. A case report and review of the literature.

Authors:  H H Bartsch; D Meyer; A T Teichmann; C P Speer
Journal:  Blut       Date:  1988-07

10.  Evaluation of hypercoagulability after remission induction chemotherapy of acute leukemia.

Authors:  E Hiller; H Riess; R Hafter; H Graeff
Journal:  Blut       Date:  1980-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.